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0939-4753/ª 2014 Elsevier B.V. All rights reseAbstract Background and aims: A high circulating ﬁbroblast growth factor 23 (FGF23) level is an
independent risk factor for cardiovascular mortality in renal transplant recipients and the gen-
eral population. N-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) may
contribute to cardiovascular risk reduction. We investigated whether ﬁsh and EPA-DHA intake
are related to FGF23 levels in renal transplant recipients.
Methods and results: We performed a cross-sectional analysis in 619 stable renal transplant recip-
ients (mean age 53 years, 57% male, estimated glomerular ﬁltration rate [eGFR] 53  20 mL/min/
1.73 m2). Dietary intake was assessed by a 177-item food frequency questionnaire. Serum intact
FGF23 was measured by ELISA. We examined differences in FGF23 levels across categories of ﬁsh
and EPA-DHA intake using analysis of variance models adjusted for age, sex, dietary and lifestyle
factors and key determinants of FGF23. Patients consumed on average 15 g of ﬁsh and 139 mg
EPA-DHA/day. Median FGF23 was 62 pg/mL (IQR 43e98 pg/mL). Higher dietary EPA-DHA and
ﬁsh intake were associated with lower serum FGF23 levels. Subgroup analyses revealed that
particularly in patients with reduced renal function (eGFR <60 mL/min/1.73 m2), adjusted
FGF23 levels (114, 79, 75 pg/mL, P Z 0.0001) were inversely associated with tertiles of EPA-
DHA intake. Similarly, we observed an inverse association between ﬁsh consumption and serum
FGF23 levels in adjusted analyses.
Conclusion: A higher intake of ﬁsh and dietary n-3 fatty acids (EPA-DHA) is related to lower circu-
lating FGF23 levels in renal transplant recipients. Further research is needed to assess the cau-
sality of this association and the clinical implications.
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rved.Introduction
Chronic kidney disease (CKD) is a worldwide health
burden, affecting about 15% of the Western adult popula-
tion. For most patients with end-stage renal disease, kid-
ney transplantation is the preferred treatment. Although
short-term graft and patient survival have improved
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limits long-term patient survival [1]. Both the incidence
and prevalence of cardiovascular disease are several times
higher in renal transplant recipients than in the general
population [2].
In patients with impaired renal function, deregulated
phosphorus metabolism characterized by elevated circu-
lating levels of the phosphaturic hormone ﬁbroblast
growth factor 23 (FGF23) plays a speciﬁc role in the
pathophysiology of cardiovascular disease. In response to
e particularly inﬂammatory e renal injury, the renal
expression of Klotho, a mandatory cofactor for the speciﬁc
FGF23 receptor, is lost [3] which may contribute to
increased circulating FGF23 levels [4]. Besides being an
indicator of impaired renal function and disturbed phos-
phorus metabolism, high circulating FGF23 levels may also
directly contribute to the development of left ventricular
hypertrophy [5]. Many epidemiologic studies have identi-
ﬁed a high FGF23 level as an independent risk factor of
cardiovascular disease and all-cause mortality in the gen-
eral population [6], across stages of CKD[7], and in renal
transplant recipients [8,9]. Consequently, strategies to
reduce FGF23 levels may have clinical impact.
Patients with impaired renal function have lower serum
levels of the n-3 fatty acids eicosapentaenoic (EPA) and
docosahexaenoic acid (DHA), mainly consumed through
ﬁsh, which may be linked to a higher cardiovascular dis-
ease risk in these patients [10]. Randomized controlled
trials in patients with chronic kidney disease (CKD)
showed a decrease in serum inﬂammatory markers after
EPA-DHA supplementation [11]. Given the role of FGF23 as
a cardiovascular risk factor in renal patients and the po-
tential cardioprotective and anti-inﬂammatory effects of n-
3 fatty acids, we investigated whether intake of ﬁsh and
EPA-DHA are related to serum FGF23 levels in a well-
deﬁned cohort of 619 renal transplant recipients.
Methods
Study population
We conducted a cross-sectional analysis in a large, single
center renal transplant recipient cohort. We invited all
renal transplant recipients (18 years) with a functioning
graft for at least one year, who visited our outpatient clinic
between November 2008 and March 2011. Renal patients
had all been transplanted in the University Medical Center
Groningen. They had sufﬁcient knowledge of the Dutch
language and no history of drug or alcohol addiction. Of
817 initially invited patients, 707 (87%) signed written
informed consent to participate in this study. After exclu-
sion of patients with missing data on dietary n-3 fatty
acids (n Z 82), missing data on eGFR (n Z 2) and FGF23
concentrations (n Z 4), data from 619 patients were
available for analyses. The Institutional Review Board on
human experimentation approved the study protocol
(METc 2008/186), which was in adherence to the Decla-
ration of Helsinki. The routine regimen included no spe-
ciﬁc dietary counseling, except for discouraging excesssodium intake and encouraging losing weight in over-
weight individuals. Renal transplant recipients were on
standard antihypertensive and immunosuppressive ther-
apy, which was as previously described [12]. Data on cur-
rent medication including vitamin D treatment
(cholecalciferol, alfacalcidol or paricalcitol) was extracted
from the medical records.
Dietary assessment
All patients adhered to their regular dietary habits during
examination. Dietary intake was assessed using a semi
quantitative food frequency questionnaire (FFQ) which
has been validated as described previously [13]. The FFQ
inquired about intake of 177 food items during the last
month. For each item, the frequency was recorded in
times per day, week, or month, and seasonal variations
were taken into account. The number of servings was
expressed in natural units (for example, slice of bread or
apple) or household measures (for example, cup or
spoon). The questionnaire was self-administered and
ﬁlled out at home. At the day of the visit to the outpatient
clinic, all FFQs were checked for completeness by a
trained researcher and inconsistent answers were veri-
ﬁed with the patients. Total energy and nutrient intake
per day was calculated using Dutch Food Composition
Tables [14]. Additionally, all participants were instructed
to collect a 24-h urine sample according to a strict pro-
tocol. Sodium intake was estimated from 24-h urine so-
dium excretion and the accuracy of FFQ for protein intake
estimation was inferred by correlating protein intake
with the protein equivalent of nitrogen appearance (PNA)
[15].
Clinical and biochemical parameters
Information on patient’s health status and medical history
was obtained from patient records. Patients received state-
of-the art treatment (Table 1), and data on current medi-
cation was extracted from the medical records. Body
weight and height were measured while participants wore
indoor clothing without shoes. Body Mass Index (BMI) was
calculated as weight divided by height squared (kg/m2).
Blood pressure (BP) was measured as described previously
[16]. Hypertension was deﬁned as BP 140/90 mmHg or
use of antihypertensive medication. Diabetes mellitus was
considered present when serum glucose was above
7 mmol/l (126 mg/dl) or when the patient used antidia-
betic medication.
Blood was drawn after an 8e12 h overnight fasting
period in the morning after completion of the 24 h urine
collection. Urinary and plasma concentrations of sodium,
chloride, potassium, calcium, phosphate and urea were
measured using routine clinical laboratory methods as
were plasma hsCRP, total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides and albumin. Intact parathyroid
hormone (PTH) was measured in EDTA plasma using
radioimmunoassay. Serum creatinine level was deter-
mined using a modiﬁed version of the Jaffé method (MEGA
Table 1 Characteristics of 619 renal transplant recipients across tertiles of EPA-DHA.
Tertiles of EPA-DHA intake (mg/d)
<39 (n Z 206) 40e158 (n Z 207) 159 (n Z 206) P value
Age (years) 51  13 53  12 54  12 0.03
Sex, n (% males) 114 (55) 117 (56) 122 (59) 0.72
BMI (kg/m2) 26  5 26  5 27  4 0.31
Waist circumference (cm) 98  15 98  15 100  14 0.19
Systolic BP (mmHg) 135  16 138  17 135  18 0.27
Diastolic BP (mmHg) 82  10 84  11 83  11 0.18
Time since transplantation (y) 6 [2e13] 6 [2e12] 6 [2e12] 0.80
Current smoker n (%) 27 [14] 21 [11] 28 [14] 0.49
Diabetes mellitus n (%) 40 [19] 31 [15] 42 [20] 0.21
Alcohol use (g/d)
No 15 [8] 22 [12] 19 [11] 0.59
1-20 g/d 145 (78) 148 (78) 139 (77)
>20 g/d 27 [14] 19 [10] 23 [13]
Energy (kcal) 2156  672 2196  601 2197  641 0.42
Medication use
Antihypertensives n (%) 183 (89) 181 (87) 180 (88) 0.90
Proliferation inhibitor n (%) 166 (81) 169 (82) 183 (89) 0.06
Mycophenolate n (%) 135 (66) 137 (66) 138 (67)
Azathioprine n (%) 31 [15] 32 [16] 45 [22]
Calcineurin inhibitor n (%) 120 (58) 127 (61) 104 (51) 0.08
Cyclosporine n (%) 80 (39) 81 (39) 89 (43)
Tacrolimus n (%) 40 [19] 41 [20] 32 [16]
Diuretics n (%) 86 (42) 82 (40) 84 (41) 0.91
Vitamin D analogues n (%) 45 [22] 52 [25] 45 [22] 0.68
Serum parameters
Creatinine (mmol/L) 121 [95e159] 130 [102e164] 124 [103e153] 0.29
eGFR(ml/min/1.73 m2)* 55  22 51  20 52  19 0.09
Urea (mmol/l) 9.3 [7.1e12.9] 9.5 [7.3e14.2] 9.8 [7.2e13.2] 0.42
PTH (pmol/l) 9.4 [5.6e14.7] 9.4 [6.3e14.5] 8.3 [5.5e13.4] 0.29
Albumin (g/l) 43  3 43  3 43  3 0.98
hsCRP (mg/l) 1.4 [0.6e3.8] 1.6 [0.6e4.2] 1.7 [0.8e5.0] 0.61
Sodium (mmol/l) 141  3 141  3 141  3 0.46
Potassium (mmol/l) 4.0  0.4 4.0  0.5 4.0  0.5 0.92
Calcium (mmol/l) 2.4  0.16 2.4  0.15 2.4  0.15 0.75
Phosphate (mmol/l) 1.0  0.2 1.0  0.2 1.0  0.7 0.52
Total cholesterol (mmol/L) 5.1  1.2 5.1  1.0 5.2  1.1 0.84
HDL cholesterol (mmol/L) 1.4  0.4 1.4  0.5 1.4  0.5 0.30
LDL cholesterol (mmol/L) 3.0  0.9 2.9  0.9 3.0  1.0 0.71
Triglycerides (mmol/L) 1.9  1.0 1.9  1.0 1.8  1.0 0.63
Urinary parameters
Creatinine (mmol/24 h) 114  36 115  33 119  31 0.32
Albumin (mg/24 h) 42 [9e184] 34 [9e172] 43 [11e152] 0.93
Sodium (mmol/24 h) 150  58 157  61 162  63 0.11
Calcium (mmol/24 h) 2.4 [1.1e3.7] 2.3 [1.0e3.9] 2.3 [1.2e3.9] 0.88
Phosphate (mmol/24 h) 24.1  9.1 24.4  8.5 25.8  8.3 0.11
Values in Table 1 are mean  SD, n(%) or median (p25ep75). P values were obtained from ANOVA for normally distributed continuous variables,
from KruskalleWallis test for skewed continuous variables and from Chi-squared test for categorical variables.
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; BP: blood pressure; *eGFR: estimated glomerular ﬁltration rate, based on Chronic
Kidney Disease-Epidemiology (CKD-EPI) Collaboration formula [17]; PTH: parathyroid hormone; hsCRP: high sensitivity C-reactive protein.
1312 L.C. Baia et al.AU 510, Merck Diagnostica, Darmstadt, Germany). Renal
function was assessed by calculating the estimated
glomerular ﬁltration rate (eGFR) applying the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [17]. Urinary albumin concentration was deter-
mined by nephelometry (Dade Behring Diagnostic, Mar-
burg, Germany). Total urinary protein concentration was
analyzed using the Biuret reaction (MEGA AU 510, Merck
Diagnostica, Darmstadt, Germany). Serum intact FGF23
levels were determined using a commercially available
ELISA kit (Kainos Laboratories, Inc., Tokyo, Japan). Intra-and inter-assay CVs are <10% and <14%, respectively [18],
reference range in healthy subjects is 10e40 pg/mL.Statistical analysis
Statistical analyses were performed using Stata (version
11.0, StataCorp, College Station, Texas, USA) and SAS sta-
tistical packages (version 9.3, SAS Institute, Cary, North
Carolina, USA). A two sided P-value <0.05 was considered
statistically signiﬁcant. Because the intakes of EPA and
Fish & omega-3 fatty acid intake and FGF23 levels after renal Tx 1313DHA were highly correlated (Spearman correlation coefﬁ-
cient: 0.99) the sum of EPA and DHA was used in the
analyses.
Descriptive analyses were performed to calculate mean
and standard deviations (SD) or medians and interquartile
range (IQR: p25, p75). Differences in baseline variables
among different categories of n-3 fatty acid consumers
were evaluated by using the KruskaleWallis test for
skewed variables, the analysis of variance (ANOVA) for
normally distributed continuous variables and Chi-squared
test for categorical data. The association between EPA-DHA
intake and lipid proﬁle (i.e. total, HDL, or LDL cholesterol or
triglyceride levels) was studies using Spearman correlation
analysis.
Backward linear regression was used to identify corre-
lates of plasma FGF23 levels. The following covariates were
tested: age, sex, donor type (deceased or living), warm and
cold ischemia times, BMI, cardiovascular history, Fra-
mingham risk score factors, eGFR, albuminuria, serum
phosphate, 24-h urinary phosphate excretion (represent-
ing phosphate intake), 24-h urinary urea excretion (rep-
resenting protein intake), high-sensitivity C-reactive
protein (hsCRP), serum albumin, hemoglobin, or NT-
proBNP levels, use of angiotensin-converting enzyme in-
hibitor or angiotensin receptor blocker, and treatment
with vitamin D analogues. Variables signiﬁcantly associ-
ated with FGF23 levels using backward linear regression
analysis were subsequently tested in a forward linear
regression model. Variables that were signiﬁcant in this
model were considered independent correlates of FGF23
levels.
To assess whether mean FGF23 levels differed accord-
ing to categories of EPA-DHA intake or ﬁsh intake ANOVA
models were used. EPA-DHA intake was divided into ter-
tiles and ﬁsh intake was categorized as 0, >0e14, and
15 g/d (because of 18% no ﬁsh eaters). Back trans-
formation was performed to obtain geometric mean FGF23
levels and 95% conﬁdence intervals in categories of ﬁsh
intake (or EPA-DHA intake). Several multivariable models
were applied, adjusting for age and sex (model 1), and for
lifestyle factors, i.e. total energy intake, alcohol use (0,Table 2 Multivariate analysis of FGF23 correlates.
Variable Standardized beta P value
eGFR (CKD-EPI) 0.27 <0.001
Serum phosphate 0.24 <0.001
NTproBNP 0.24 <0.001
Urinary phosphate excretion 0.17 <0.001
Triglycerides 0.12 <0.001
Age 0.10 0.01
Gender (0Z male; 1 Z female) 0.10 0.01
Smoking (0Z never; 1 Z ever) 0.08 0.01
Parathyroid hormone 0.07 0.045
Albuminuria 0.07 0.049
Excluded from the model: use of RAAS blockers or vitamin D ana-
logues, cold and warm ischemia times, time since transplantation,
hemoglobin, donor status (living or deceased), presence of diabetes
mellitus, BMI, urinary urea excretion, serum cholesterol, hsCRP.
Model ﬁt: R2 0.40.>0e20, >20 g/d), smoking status and BMI (model 2). P-
values for the differences in dietary intake were obtained
from the KruskaleWallis test for skewed variables. Based
on the outcomes of this analysis, we additionally adjusted
our data for fruit and vegetables intake (model 3) on the
assumption that ﬁsh consumers are more likely than are
ﬁsh non-consumers to follow a healthy diet rich in fruits
and vegetables [19]. Finally, known determinants of FGF23,
i.e. serum calcium, phosphate and PTH were added to the
full model (model 4).
The association between ﬁsh or EPA-DHA intake and
serum FGF23 was analyzed for an interaction by eGFR,
either as a dichotomous or continuous variable, by adding
an interaction term (eGFRxFGF23) to all ANOVA models.
Because a signiﬁcant interaction term was found
(P < 0.0001), we repeated the analyses in strata of renal
graft function (eGFR <60 vs. 60 mL/min/1.73 m2).
Results
Patient characteristics
Patients were on average 53  13 years old and 57% was
male. The mean BMI was 26.7  4.8 kg/m2, with 59% of the
patients being overweight. The median time since trans-
plantation was 5.4 [1.9e12.2] years. Mean systolic blood
pressure was 136/83 mmHg and 91% of the cohort had
hypertension. The mean ﬁsh intake was 15 g/d, which
corresponds to approximately one serving per week, and
EPA-DHA intake was 139 mg/d. The median serum intact
FGF23 level was 62 [IQR: 43e98] pg/mL. Patients with a
reduced graft function (eGFR<60 mL/min/1.73 m2,
n Z 403, 65%) had a serum FGF23 concentration of 78
[IQR: 54e121] pg/mL, which was higher than in those with
a normal graft function (n Z 216, 47 pg/mL [IQR: 35e61];
P < 0.001). Patient characteristics in tertiles of EPA-DHA
intake are shown in Table 1. Those who had a higher
EPA-DHA intake were slightly older (P Z 0.03). No sig-
niﬁcant differences were observed in cardiovascular risk
factors, medication use, or other clinical parameters. EPA-
DHA intake was not associated with lipid proﬁle (HDL, LDL,
total cholesterol or triglycerides) or hsCRP. Multivariate
regression analysis revealed independent determinants of
FGF23 levels in our cohort (Table 2).
Fish consumption and circulating FGF23
Circulating FGF23 levels were inversely related to ﬁsh
intake (Table 3), with geometric mean levels of 78.0 pg/mL
for 0 g/d, 73.3 pg/mL for 1e14 g/d and 64.4 pg/mL for
15 g/d (P-trend Z 0.06) after adjustment for age, sex,
BMI and dietary and lifestyle factors (model 3). After
adjustment for key determinants of FGF23 (serum calcium,
phosphate and PTH), the association became statistically
signiﬁcant (P Z 0.03, Table 3, model 4). The association
between ﬁsh intake and FGF23 levels was inﬂuenced by
eGFR (P-interaction <0.0001 in all models). In patients
with a reduced graft function (eGFR <60 mL/min/1.73 m2),
FGF23 levels were 108.9 pg/mL, 89.5 pg/mL and 77.0 pg/
Table 3 Fish intake and serum FGF23 levels (pg/mL)a in 619 renal transplant patients, in the total cohort and stratiﬁed by renal graft function.
Fish intake (g/d)
0 1e14 15 P-value
Total cohort
N 108 234 277
Model 1 72.3 (63.0e82.9) 72.0 (65.6e79.0) 64.5 (59.2e70.2) 0.167
Model 2 76.7 (66.3e88.8) 73.5 (66.4e81.4) 64.2 (58.5e70.5) 0.063
Model 3 76.9 (66.4e89.0) 73.4 (66.2e81.4) 64.3 (58.4e70.6) 0.067
Model 4* 76.7 (68.1e86.4) 75.5 (69.4e82.1) 62.8 (58.1e67.8) 0.002
Patients with eGFR <60 mL/min/1.73 m2.
N 62 149 192
Model 1 99.5 (82.5e120.0) 91.4 (81.0e103.1) 75.8 (68.1e84.3) 0.015
Model 2 106.7 (87.3e130.4) 93.1 (81.4e106.4) 75.2 (67.1e84.4) 0.005
Model 3 107.6 (88.0e131.6) 92.2 (80.5e105.6) 75.3 (67.1e84.6) 0.005
Model 4 107.3 (89.7e128.3) 89.6 (79.4e101.2) 77.0 (69.5e85.3) 0.005
Patients with eGFR 60 mL/min/1.73 m2.
N 46 85 85
Model 1 46.1 (40.4e52.5) 47.4 (43.1e52.1) 45.2 (41.1e49.7) 0.784
Model 2 49.1 (42.9e56.2) 48.8 (44.1e53.9) 42.2 (37.9e47.0) 0.104
Model 3 48.7 (42.5e55.7) 49.3 (44.6e54.5) 42.2 (37.9e47.0) 0.091
Model 4 48.1 (42.4e54.5) 49.5 (45.1e54.4) 42.3 (38.3e46.8) 0.071
a FGF23 levels are geometric means (95% conﬁdence interval).
Model 1 Z age and gender adjusted Model 2 Z model 1 þ energy intake, alcohol consumption, smoking status, BMI and use of vitamin D
analogues Model 3 Z model 2 þ vegetables and fruit Model 4 Z model 3 þ serum calcium, phosphate and PTH Model 4* Z model 3 þ eGFR,
serum calcium, phosphate and PTH.
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using the fully adjusted model. The association was not
signiﬁcant in those with normal graft function (P > 0.2,
Table 3).EPA-DHA intake and circulation FGF23
Circulating FGF23 levels decreased with increasing EPA-
DHA intake (Table 4), with geometric mean levels of
81.9 pg/mL for <39 mg/d, 63.9 pg/mL for 40e158 mg/d and
65.6 pg/mL for 159 mg/d (P Z 0.003) after adjustment
for age, sex, BMI and dietary and lifestyle factors (model 3).
After further adjustment for key determinants of FGF23,
this inverse association remained (P Z 0.001, Table 4). As
for ﬁsh intake, the association between EPA-DHA intake
and FGF23 was inﬂuenced by eGFR (P-interaction <0.0001
in all models). In patients with a reduced graft function
(eGFR <60 mL/min/1.73 m2), FGF23 levels were 109.6 pg/
mL, 77.9 pg/mL and 78.2 pg/mL (P-trend Z 0.0002) in
consecutive tertiles of EPA-DHA, using the fully adjusted
model 4 (Fig. 1). In those with an eGFR >60 mL/min/
1.73 m2, the association with EPA-DHA intake was also
signiﬁcant (P Z 0.004), but FGF23 levels were 50% lower
than in those with reduced graft function (Table 4). Further
adjustments for urinary sodium and phosphate excretion
did not alter the results.
Discussion
The main ﬁnding of the current study is the inverse as-
sociation of ﬁsh and dietary intake of n-3 long-chainpolyunsaturated fatty acids (EPA-DHA) with serum FGF23
levels in a large cohort of renal transplant recipients.
Particularly in patients with reduced graft function (eGFR
<60 mL/min/1.73 m2) circulating FGF23 levels were
reduced with increasing tertiles of EPA-DHA or categories
of ﬁsh intake.
Daily intake of ﬁsh (w15 g/d) and EPA-DHA (w139 mg/
d) in our cohort of renal transplant recipients was well
below the recommended intake levels of two servings of
ﬁsh per week, equaling 450 mg/d EPA-DHA [20]. Similar
low levels of intake (15 g/d ﬁsh) were also observed in a
recent clinical trial in post-myocardial infarction patients
in The Netherlands [21]. A strong point of the present
study is the large, well-characterized cohort of renal
transplant recipients, with extensive dietary data collec-
tion, serum samples and 24-h urinary samples. This
enabled us to adjust for many potential dietary con-
founders, including 24-h sodium and phosphate excretion.
Nevertheless, since this is an observational study, we
cannot exclude the possibility of residual confounding by
(unmeasured) dietary or lifestyle factors, such as physical
activity, that could potentially have inﬂuenced serum
FGF23 in our patients. Furthermore, we did not measure a
circulating biomarker of n-3 fatty acid content to conﬁrm
the association between n-3 fatty acid intake and FGF23
levels. Another limitation is the cross-sectional nature of
our study, and patients may have intentionally changed
their diets for health-related reasons. On the other hand,
since ﬁsh is not a major contributor to total daily protein
and mineral intakes, we consider it unlikely that patients
have been advised to change their intake of ﬁsh. Finally,
we did not adjust for serum vitamin D levels or dietary
Table 4 EPA-DHA intake and serum FGF23 levels (pg/mL)# in 619 renal transplant patients, in the total cohort and stratiﬁed by renal graft
function.
EPA-DHA intake (mg/d)
<39 40e158 159 P-value
Total cohort
N 206 207 206
Model 1 76.9 (69.6e84.9) 64.9 (58.8e71.6) 64.7 (58.6e71.4) 0.022
Model 2 81.2 (72.9e90.4) 64.1 (57.6e71.2) 63.3 (58.6e72.9) 0.004
Model 3 81.3 (72.9e90.5) 64.1 (57.6e71.4) 65.3 (58.4e72.9) 0.004
Model 4* 86.5 (79.3e94.3) 62.1 (57.0e67.6) 63.4 (58.0e69.3) <0.0001
Patients with eGFR <60 mL/min/1.73 m2.
N 116 141 146
Model 1 106.4 (92.9e121.9) 80.0 (70.8e90.4) 74.6 (66.2e84.2) 0.0004
Model 2 113.1 (97.4e131.2) 78.6 (68.9e89.7) 75.4 (66.1e86.1) 0.0001
Model 3 112.7 (97.0e131.0) 78.7 (69.0e89.8) 75.3 (65.9e86.0) 0.0002
Model 4 108.3 (94.7e123.8) 78.0 (69.3e87.8) 78.4 (69.6e88.0) 0.0003
Patients with eGFR 60 mL/min/1.73 m2.
N 90 66 60
Model 1 50.3 (45.9e55.2) 41.6 (37.4e46.3) 45.7 (40.9e51.1) 0.030
Model 2 53.0 (48.3e58.2) 40.2 (36.0e44.8) 44.0 (38.9e49.7) 0.001
Model 3 52.7 (48.0e58.0) 40.0 (35.8e44.8) 44.9 (39.6e50.9) 0.001
Model 4 52.7 (48.2e57.5) 41.3 (37.2e45.9) 43.3 (38.5e48.7) 0.001
aFGF23 levels are geometric means (95% conﬁdence interval).
Model 1 Z age and gender adjusted Model 2 Z model 1 þ energy intake, alcohol consumption, smoking status, BMI and use of vitamin D
analogues Model 3 Z model 2 þ vegetables and fruit Model 4 Z model 3 þ serum calcium, phosphate and PTH Model 4* Z model 3 þ eGFR,
serum calcium, phosphate and PTH.
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present cohort. Treatment with vitamin D analogues did
however not contribute to FGF23 levels, nor did it inﬂu-
ence the association between EPA-DHA intake and FGF23
levels.
Although our data do not allow us to draw conclusions
on how ﬁsh or EPA-DHA could regulate FGF23 levels, we
can speculate on a potential mechanism through anti-
inﬂammatory effects increasing renal klotho expression.
Pro-inﬂammatory cytokines have been linked to a revers-
ible klotho down-regulation in the kidney [23]. In line,
FGF23 levels have recently been linked with systemicFigure 1 Serum FGF23 levels (pg/mL) according to tertiles of dietary
EPA-DHA intake stratiﬁed by renal graft function (eGFR above or below
60 mL/min/1.73 m2).inﬂammation in CKD [24]. The inverse association be-
tween EPA-DHA intake and FGF23 could therefore be
explained by a partial restoration of renal klotho expres-
sion due to its anti-inﬂammatory effects on tubular
epithelial cells [25]. Also, n-3 fatty acids may increase the
expression of antioxidant genes [26], and oxidative stress
has been associated with lower klotho expression [27]. Of
interest, interventions that reduced oxidative stress
partially restored renal klotho expression in animal
models [28]. As an alternative explanation, n-3 fatty acids
could act directly on the PTH receptor, a potent inducer of
FGF23 [29]; yet adjustment for phosphate, calcium and
PTH did not change the observed association between n-3
fatty acid or ﬁsh intake and FGF23.
Serum FGF23 levels have been shown to be inﬂuenced
by phosphate-rich foods, particularly by protein from an-
imal sources. Yet the most important factor contributing to
FGF23 levels is suggested to be inorganic phosphate [30].
In summary, the present study showed for the ﬁrst time
that ﬁsh and EPA-DHA intake are associated with serum
FGF23 levels in a large cohort of renal transplant re-
cipients. Future prospective studies should address
whether increased ﬁsh or EPA-DHA intake could be new
strategies to reduce cardiovascular morbidity and mortal-
ity after kidney transplantation through reduction of
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